Plus   Neg

Stock Alert: Tenax Shares Soar 72% In Premarket On Phase 2 Trial Results Of Levosimendan

Shares of Tenax Therapeutics Inc. (TENX) are surging over 72% in pre-market today, after the specialty pharmaceutical company announced positive Phase 2 results for levosimendan for the treatment of patients with pulmonary hypertension and heart failure with preserved ejection fraction.

The company noted that in this 37 patient study, the primary efficacy analysis, pulmonary capillary wedge pressure (PCWP) during exercise did not demonstrate a statistically significant reduction from baseline.

Levosimendan did demonstrate a statistically significant reduction in PCWP compared to baseline and placebo when the measurements at rest, with legs up and on exercise were combined. Levosimendan also demonstrated a statistically significant improvement in 6-minute walk distance as compared to placebo.

Dr. Stuart Rich, Professor of Medicine at the Bluhm Cardiovascular Institute at Northwestern University commented, "Levosimendan is the first drug to ever show a favorable mechanism of action with biventricular effects in patients with PH-HFpEF..."

The stock has been trading in the range of $0.25 - $1.77 for the past one year, and closed Monday's trade at $1.45, up 1 cent or 0.69%. TENX is currently trading at $2.50, up $1.05 or 72.41% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT